266 related articles for article (PubMed ID: 12496469)
21. Bioreductive therapy.
Chaplin DJ
Int J Radiat Oncol Biol Phys; 1992; 22(4):685-7. PubMed ID: 1544837
[No Abstract] [Full Text] [Related]
22. [Can tumor hypoxia be turned into a chemotherapeutic advantage?].
Trédan O; Grantab R; Dumontet C
Bull Cancer; 2008 May; 95(5):528-34. PubMed ID: 18541517
[TBL] [Abstract][Full Text] [Related]
23. Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.
De Ridder M; Van Esch G; Engels B; Verovski V; Storme G
Bull Cancer; 2008 Mar; 95(3):282-91. PubMed ID: 18390408
[TBL] [Abstract][Full Text] [Related]
24. Novel radiation sensitizers targeting tissue hypoxia.
Rowinsky EK
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):61-70. PubMed ID: 10550828
[TBL] [Abstract][Full Text] [Related]
25. The Japanese experiences with hypoxia-targeting pharmacoradiotherapy: from hypoxic cell sensitisers to radiation-activated prodrugs.
Shibamoto Y; Sugie C; Ito M; Ogino H
Expert Opin Pharmacother; 2004 Dec; 5(12):2459-67. PubMed ID: 15571464
[TBL] [Abstract][Full Text] [Related]
26. Hypoxia inducible factor as a cancer drug target.
Welsh SJ; Powis G
Curr Cancer Drug Targets; 2003 Dec; 3(6):391-405. PubMed ID: 14683498
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
Rohwer N; Cramer T
Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
[TBL] [Abstract][Full Text] [Related]
28. Radiation sensitization with redox modulators: a promising approach.
Rosenberg A; Knox S
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):343-54. PubMed ID: 16414370
[TBL] [Abstract][Full Text] [Related]
29. Improving the effectiveness of the bioreductive antitumor agent SR 4233 by induced hypoxia.
Minchinton AI; Brown JM
Adv Exp Med Biol; 1992; 317():177-81. PubMed ID: 1288125
[No Abstract] [Full Text] [Related]
30. Enhanced effectiveness of radiochemotherapy with tirapazamine by local application of electric pulses to tumors.
Maxim PG; Carson JJ; Ning S; Knox SJ; Boyer AL; Hsu CP; Benaron DA; Walleczek J
Radiat Res; 2004 Aug; 162(2):185-93. PubMed ID: 15387146
[TBL] [Abstract][Full Text] [Related]
31. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia.
Gandara DR; Lara PN; Goldberg Z; Le QT; Mack PC; Lau DH; Gumerlock PH
Semin Oncol; 2002 Feb; 29(1 Suppl 4):102-9. PubMed ID: 11894020
[TBL] [Abstract][Full Text] [Related]
32. The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture.
Brown JM
Cancer Res; 1999 Dec; 59(23):5863-70. PubMed ID: 10606224
[TBL] [Abstract][Full Text] [Related]
33. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation.
Brown JM; Lemmon MJ
Int J Radiat Oncol Biol Phys; 1991 Mar; 20(3):457-61. PubMed ID: 1995531
[TBL] [Abstract][Full Text] [Related]
34. Tirapazamine sensitizes hepatocellular carcinoma cells to topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1α.
Cai TY; Liu XW; Zhu H; Cao J; Zhang J; Ding L; Lou JS; He QJ; Yang B
Mol Cancer Ther; 2014 Mar; 13(3):630-42. PubMed ID: 24362462
[TBL] [Abstract][Full Text] [Related]
35. Bioreductive drugs: from concept to clinic.
McKeown SR; Cowen RL; Williams KJ
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):427-42. PubMed ID: 17482438
[TBL] [Abstract][Full Text] [Related]
36. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.
Yeo EJ; Chun YS; Cho YS; Kim J; Lee JC; Kim MS; Park JW
J Natl Cancer Inst; 2003 Apr; 95(7):516-25. PubMed ID: 12671019
[TBL] [Abstract][Full Text] [Related]
37. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
Brown JM
Br J Cancer; 1993 Jun; 67(6):1163-70. PubMed ID: 8512801
[TBL] [Abstract][Full Text] [Related]
38. The role of hypoxia-activated prodrugs in cancer therapy.
Denny WA
Lancet Oncol; 2000 Sep; 1(1):25-9. PubMed ID: 11905684
[TBL] [Abstract][Full Text] [Related]
39. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors.
Shulman LN; Buswell L; Riese N; Doherty N; Loeffler JS; von Roemeling RW; Coleman CN
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):349-53. PubMed ID: 10760430
[TBL] [Abstract][Full Text] [Related]
40. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies.
Shannon AM; Bouchier-Hayes DJ; Condron CM; Toomey D
Cancer Treat Rev; 2003 Aug; 29(4):297-307. PubMed ID: 12927570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
